Heike Wulff

This inventor holds 12 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: University of California, Louisiana State University and Agricultural & Mechanical College, The Board of Supervisors of Louisiana State Univer University and Agricultural and Mechanical Colleg. Active years: 2004-2026.

USPTO Granted Patents = 12 (Patent Applications = 3)

% Patents Active = 50.0

CIPO Patents = 1

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 3.5

ph-index = 1

Forward Citations = 3(Granted Patents)

Location History:

Irvine, CA (US) (2004 - 2010)
Davis, CA (US) (2009 - 2024)

Company Filing History:

10 out of 15,964

University of California

patents

1 out of 838

Louisiana State University and Agricultural & Mechanical College

patents

1 out of 1

The Board of Supervisors of Louisiana State Univer University and Agricultural and Mechanical Colleg

patent

4. 1 out of 84

Walter and Eliza Hall Institute of Medical Research

patents

5. 1 out of 834,307

Other

patents

where one patent can have more than one assignee

Years Active: 2004-2026

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12661340 - NEUROPROTECTIVE COMPOSITIONS AND METHODS OF USING THE SAME (2026-06-23),

2. 11974988 - Neuroprotective compositions and methods of using the same (2024-05-07),

3. 11173146 - Selective activators of the intermediate conductance CA2+activated K+ channel KCa3.1 and their methods of use (2021-11-16),

4. 9675591 - Methods for treating seizure disorders and pain (2017-06-13),

5. 8067460 - 5-phenoxyalkoxypsoralens and methods for selective inhibition of the voltage gated Kv1.3 potassium channel (2011-11-29),

6. 8063093 - Potassium channel blockers and uses thereof (2011-11-22),

7. 8026263 - Methods for inhibiting neoproliferative changes in blood vessel walls (2011-09-27),

8. 7772408 - Substituted 5-alkoxypsoralens as inhibitors of potassium channel activity in lymphocytes and other cells (2010-08-10),

9. 7557138 - [object Object] (2009-07-07),

10. 7507839 - Therapeutic ion channel blocking agents and methods of use thereof (2009-03-24),

11. 7235577 - Non-peptide inhibition of T-lymphocyte activation and therapies related thereto (2007-06-26),

12. 6803375 - Non-peptide inhibition of T-lymphocyte activation and therapies related thereto (2004-10-12),

Title: Heike Wulff: Innovator in Neuroprotective Compositions

Introduction

Heike Wulff is a prominent inventor based in Davis, CA (US). He has made significant contributions to the field of neuroprotective compositions, holding a total of 12 patents. His work focuses on developing methods to treat neurodegenerative diseases, showcasing his commitment to advancing medical science.

Latest Patents

Wulff's latest patents include innovative neuroprotective compositions and methods for their use. One notable invention is directed towards neuroprotective compositions aimed at treating neurodegenerative diseases. Another significant patent involves selective activators of the intermediate conductance CA2+ activated K+ channel KCa3.1, which includes benzoxazole and indole type KCa3.1 activators. These compounds have therapeutic uses in both human and animal subjects, as well as applications in the ex vivo preservation of organs or tissues.

Career Highlights

Throughout his career, Heike Wulff has worked with esteemed institutions such as the University of California and Louisiana State University and Agricultural & Mechanical College. His research has been pivotal in the development of new therapeutic strategies for neurodegenerative conditions.

Collaborations

Wulff has collaborated with notable colleagues, including K George Chandy and Nichole Coleman, who have contributed to his research endeavors.

Conclusion

Heike Wulff's innovative work in neuroprotective compositions and his collaborations with leading researchers highlight his significant impact on the field of medical science. His contributions continue to pave the way for advancements in treating neurodegenerative diseases.